Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Renata Rao

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Journal of Neurology|February 24, 2026
Could galcanezumab modulate inflammatory cytokines? A single-centre exploratory studyGiulia Ceccardi, Renata Rao, Francesca Schiano di Cola, et al.
Neurology. Clinical Practice|January 7, 2022
Erenumab Discontinuation After 12-Month Treatment: A Multicentric, Observational Real-Life StudyFrancesca Schiano di Cola, Salvatore Caratozzolo, Elisabetta Venturelli, et al.
Headache|October 14, 2025
Comprehensive assessment of erenumab efficacy in participants with high-frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE studyGabriel Paiva da Silva Lima, Renata Rao, Gyöngyi Szabó, et al.
Headache|June 14, 2021
Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real-life perspective from the Italian chROnic migraiNe (IRON) projectPiero Barbanti, Luisa Fofi, Licia Grazzi, et al.
The Journal of Headache and Pain|December 19, 2021
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort studyFabrizio Vernieri, Nicoletta Brunelli, Roberta Messina, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 16, 2025
The second interim analysis of Italian participants enrolled in the real-world, Pan-European, prospective, observational, Phase 4 PEARL study of fremanezumab effectivenessFabrizio Vernieri, Anna Ambrosini, Marco Bartolini, et al.
Neurology and Therapy|February 8, 2024
Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY)Fabrizio Vernieri, Luigi Francesco Iannone, Simona Guerzoni, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 18, 2026
Building bridges in migraine management: consensus pathways on best practices across primary and specialist care in ItalyPiero Barbanti, Cristina Tassorelli, Fabrizio Vernieri, et al.
European Journal of Neurology|September 13, 2022
Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT studyFabrizio Vernieri, Nicoletta Brunelli, Marilena Marcosano, et al.
Journal of Neurology|July 19, 2023
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO studyFabrizio Vernieri, Nicoletta Brunelli, Simona Guerzoni, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Journal of Neurology|February 24, 2026
Could galcanezumab modulate inflammatory cytokines? A single-centre exploratory studyGiulia Ceccardi, Renata Rao, Francesca Schiano di Cola, et al.
Neurology. Clinical Practice|January 7, 2022
Erenumab Discontinuation After 12-Month Treatment: A Multicentric, Observational Real-Life StudyFrancesca Schiano di Cola, Salvatore Caratozzolo, Elisabetta Venturelli, et al.
Headache|October 14, 2025
Comprehensive assessment of erenumab efficacy in participants with high-frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE studyGabriel Paiva da Silva Lima, Renata Rao, Gyöngyi Szabó, et al.
Headache|June 14, 2021
Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real-life perspective from the Italian chROnic migraiNe (IRON) projectPiero Barbanti, Luisa Fofi, Licia Grazzi, et al.
The Journal of Headache and Pain|December 19, 2021
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort studyFabrizio Vernieri, Nicoletta Brunelli, Roberta Messina, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 16, 2025
The second interim analysis of Italian participants enrolled in the real-world, Pan-European, prospective, observational, Phase 4 PEARL study of fremanezumab effectivenessFabrizio Vernieri, Anna Ambrosini, Marco Bartolini, et al.
Neurology and Therapy|February 8, 2024
Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY)Fabrizio Vernieri, Luigi Francesco Iannone, Simona Guerzoni, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 18, 2026
Building bridges in migraine management: consensus pathways on best practices across primary and specialist care in ItalyPiero Barbanti, Cristina Tassorelli, Fabrizio Vernieri, et al.
European Journal of Neurology|September 13, 2022
Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT studyFabrizio Vernieri, Nicoletta Brunelli, Marilena Marcosano, et al.
Journal of Neurology|July 19, 2023
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO studyFabrizio Vernieri, Nicoletta Brunelli, Simona Guerzoni, et al.
Pageof 4